Bristol-Myers Squibb Co. [BMY] Is Currently 1.84 below its 200 Period Moving Avg: What Does This Mean?

Bristol-Myers Squibb Co. [NYSE: BMY] traded at a high on Thursday, posting a 1.84 gain after which it closed the day’ session at $54.23. The company report on March 29, 2024 at 9:45 AM that Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes.

Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United Kingdom.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The results of the trading session contributed to over 13511344 shares changing hands. Over the past one week, the price volatility of Bristol-Myers Squibb Co. stands at 1.64% while the volatility over the past one month is 1.97%.

The market cap for BMY stock reached $109.66 billion, with 2.02 billion shares outstanding and 2.02 billion shares in the current float. Compared to the average trading volume of 16.72M shares, BMY reached a trading volume of 13511344 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Bristol-Myers Squibb Co. [BMY]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $56.34 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 2.63. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Societe Generale have made an estimate for Bristol-Myers Squibb Co. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on March 11, 2024. While these analysts kept the previous recommendation, Redburn Atlantic dropped their target price from $77 to $54. The new note on the price target was released on February 06, 2024, representing the official price target for Bristol-Myers Squibb Co. stock. Previously, the target price had yet another drop from $68 to $60, while BofA Securities kept a Neutral rating on BMY stock. On November 15, 2023, analysts decreased their price target for BMY shares from 68 to 55.

The Average True Range (ATR) for Bristol-Myers Squibb Co. is set at 1.04, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 2.44. The Price to Book ratio for the last quarter was 3.72, with the Price to Cash per share for the same quarter was set at 6.10. Price to Free Cash Flow for BMY in the course of the last twelve months was 8.67 with Quick ratio for the last quarter at 1.31.

How has BMY stock performed recently?

Bristol-Myers Squibb Co. [BMY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.12. With this latest performance, BMY shares gained by 6.50% in over the last four-week period, additionally sinking by -6.32% over the last 6 months – not to mention a drop of -20.48% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 67.21, with the RSI for the last a single of trading hit 72.69, and the three-weeks RSI is set at 63.53 for Bristol-Myers Squibb Co. [BMY]. The present Moving Average for the last 50 days of trading for this stock 50.88, while it was recorded at 52.84 for the last single week of trading, and 55.59 for the last 200 days.

Bristol-Myers Squibb Co. [BMY]: Deeper insight into the fundamentals

Bristol-Myers Squibb Co.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.31 and a Current Ratio set at 1.43.

Earnings analysis for Bristol-Myers Squibb Co. [BMY]

With the latest financial reports released by the company, Bristol-Myers Squibb Co. posted 2.05/share EPS, while the average EPS was predicted by analysts to be reported at 1.97/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Co. go to -2.80%.

Insider trade positions for Bristol-Myers Squibb Co. [BMY]

The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in BMY stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in BMY stock with ownership which is approximately 5.8325%.